PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session
作者: Muhammad W. Saif
刊名: Pancreas - Open Journal, 2019, Vol.3 (1)
来源数据库: Openventio Publishers
DOI: 10.17140/POJ-3-e011
关键词: Pancreatic cancerChemoresistanceDNA damage repairSynthetic lethalityBRCA1/2Germline mutationsGenomics
原始语种摘要: Survival rates for pancreatic cancer remain dismal. Current standard of care treatment regimens provide transient clinical benefit but eventually chemoresistance develops. Tumors deficient in deoxyribonucleic acid (DNA) damage repair mechanisms such as BRCA mutants show better responses to platinum based agents, however, such tumors can utilize the poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) pathway as a salvage mechanism. Therefore, inhibition of PARP pathway could lead to tumor destruction and synthetic lethality in presence of BRCA mutation. Various PARP inhibitors have been approved for treatment of patients with germline or somatic BRCA mutant breast and ovarian cancer. This provides basis of using PARP inhibitors in patients with pancreatic cancer that harbor BRCA...
全文获取路径: PDF下载  Openventio出版社 
分享到:

×
关键词翻译
关键词翻译
  • pancreatic 胰的
  • Cancer 巨蟹座
  • ovarian 卵巢的
  • breast 胸部
  • dismal 浅沼泽
  • survival 生存
  • repair 修理
  • platinum 
  • cancer 癌症
  • lethality 死亡率